Prof. Dr. med. Martin Glas - Neuroonkologie, Essen - Publikationen

  • Journal of Clinical Oncology (2016: IF 24.008):
  • Herrlinger U, ..., Glas M. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol 2016;34:1611-1619.
  • Schäfer N, ..., Glas M. Vemurafenib for leptomeningeal melanomatosis. J Clin Oncol 2013;31:173-174.
  • Stuplich M, Hadizadeh DR, Kuchelmeister K, Scorzin J, Filss C, Langen KJ, Schaefer N, Mack F, Schueller H, Simon M, Glas M, Pietsch T, Urbach H, Herrlinger U. Late and prolonged pseudoprogression in glioblastoma after CCNU and temozolomide. J Clin Oncol 2012;30:e180-3.
  • Glas M, Happold C, Rieger J, et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 2009;27:1257-1261.


  • Weitere Hauptveröffentlichungen:
  • Kebir S, ..., Glas M. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases. Neuro-Oncology 2016;18:1462-1464. (IF 7,37)
  • Herrlinger U, Jones DT, Glas M*, et al. Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathol 2015;131:309-319. *shared first authorship. (IF 10,76)
  • Wieland A, ..., Glas M*, Scheffler B*. Anticancer effects of niclosamide in human glioblastoma. Clin Cancer Res 2013;19:4124-4136. *shared last authorship. (IF 7,74)
  • Glas M, Coch C, Trageser D, et al. Targeting the Cytosolic Innate Immune Receptors RIG-I and MDA5 Effectively Counteracts Cancer Cell Heterogeneity in Glioblastoma. Stem Cells 2013;31:1064-1074. (IF 7,78)
  • Glas M, Bähr O, Felsberg J, et al. NOA-05 phase 2 trial of procarbazine and lomustine in gliomatosis cerebri. Ann Neurol 2011;70:445-453. (IF 10,75)
  • Li Y, Li A, Glas M, et al. C-Met Signaling Induces a Reprogramming Network and Supports the Glioblastoma Stem-Like Phenotype. Proc Natl Acd Sci USA 2011;108:9951-9956. (IF 9,78)
  • Glas M, Rath BH, Simon M, et al. Residual tumor cells are unique cellular targets in glioblastoma. Ann Neurol 2010;68:264-269. (IF 10,75)